Jane Alty, Lynette R Goldberg, Eddy Roccati, Katherine Lawler, Quan Bai, Guan Huang, Aidan D Bindoff, Renjie Li, Xinyi Wang, Rebecca J St George, Kaylee Rudd, Larissa Bartlett, Jessica M Collins, Mimieveshiofuo Aiyede, Nadeeshani Fernando, Anju Bhagwat, Julia Giffard, Katharine Salmon, Scott McDonald, Anna E King, James C Vickers
BACKGROUND: Dementia prevalence is predicted to triple to 152 million globally by 2050. Alzheimer's disease (AD) constitutes 70% of cases. There is an urgent need to identify individuals with preclinical AD, a 10-20-year period of progressive brain pathology without noticeable cognitive symptoms, for targeted risk reduction. Current tests of AD pathology are either too invasive, specialised or expensive for population-level assessments. Cognitive tests are normal in preclinical AD...
April 16, 2024: BMC Neurology